Evidence map›Paper›PMID 30802897›Full record

Trial reportAnnals of internal medicine2019

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Rajnish Mehrotra, Daniel Cukor, Mark Unruh, Tessa Rue, Patrick Heagerty, Scott D Cohen, Laura M Dember, Yaminette Diaz-Linhart, Amelia Dubovsky, Tom Greene and 9 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Annals of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02358343 (ASCEND), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02358343 phase3completednot on this map

ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression

TypeinterventionalSponsorUniversity of WashingtonRan2015 to 2017Enrolled184ConditionsDepression, End Stage Renal DiseaseArmsEngagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Mental health and kidney disease.Nature reviews. Nephrology · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Rajnish MehrotraUniversity of Washington, Seattle, Washington (R.M., T.R., P.H., A.D., N.G.).
Daniel CukorState University of New York Downstate Medical Center, Brooklyn, New York (D.C., N.V.).
Mark UnruhUniversity of New Mexico, Albuquerque, New Mexico (M.U., D.K.Q.).
Tessa RueUniversity of Washington, Seattle, Washington (R.M., T.R., P.H., A.D., N.G.).
Patrick HeagertyUniversity of Washington, Seattle, Washington (R.M., T.R., P.H., A.D., N.G.).
Scott D CohenGeorge Washington University, Washington, DC (S.D.C.).
Laura M DemberUniversity of Pennsylvania, Philadelphia, Pennsylvania (L.M.D.).
Yaminette Diaz-LinhartBoston University, Boston, Massachusetts (Y.D.).
Amelia DubovskyUniversity of Washington, Seattle, Washington (R.M., T.R., P.H., A.D., N.G.).
Tom GreeneUniversity of Utah, Salt Lake City, Utah (T.G.).
Nancy GroteUniversity of Washington, Seattle, Washington (R.M., T.R., P.H., A.D., N.G.).
Nancy KutnerEmory University, Atlanta, Georgia (N.K.).
Madhukar H TrivediUniversity of Texas Southwestern, Dallas, Texas (M.H.T., S.S.H.).
Davin K QuinnUniversity of New Mexico, Albuquerque, New Mexico (M.U., D.K.Q.).
Nisha Ver HalenState University of New York Downstate Medical Center, Brooklyn, New York (D.C., N.V.).
Steven D WeisbordVeterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, Pittsburgh, Pennsylvania (S.D.W.).
Bessie A YoungVeterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington (B.A.Y.).
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (P.L.K.).
S Susan HedayatiUniversity of Texas Southwestern, Dallas, Texas (M.H.T., S.S.H.).
University of Washington · USSUNY Downstate Health Sciences University · USThe University of Texas Southwestern Medical Center · USUniversity of New Mexico · USBoston University · USEmory University · USGeorge Washington University · USNational Institutes of Health · USUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Utah · US

Funding

Randomized trial of sertraline treatment of depression in Chronic Kidney DiseaseR01DK085512 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HEDAYATI, SUSAN · 2011 to 2015
$1.8M
NIDDK NIH HHS R01 DK085512
6 · The paper itself

Abstract

Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343). Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms-Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, -12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, -1.84 [CI, -3.54 to -0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

Indexed as

Interview, PsychologicalPatient Acceptance of Health CareRenal DialysisAdultAntidepressive AgentsCognitive Behavioral TherapyComparative Effectiveness ResearchDepressionFemaleFollow-Up StudiesHumansKidney Failure, ChronicMaleMiddle AgedPatient CompliancePatient Reported Outcome MeasuresAntidepressive AgentsSertraline

Identifiers

PMID30802897
OpenAlexW2916965599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.